Articles related to ULCERATIVE COLITIS (UC)
A Study of the Association of Ulcerative Colitis and Bipolar Disorder in an Inpatient Population
This study’s findings challenge existing understanding by revealing an inverse relationship between ulcerative colitis and bipolar disorder in young adult inpatients. The results, based on a vast sample size and national representation, call for further research to uncover the underlying mechanisms and potential therapeutic implications.
Gastroenterology August 22nd 2023
‘Infect and Forget’: A Dose of Hookworms Could Help Patients Manage Inflammatory Bowel Disease
Pioneering research from the Malaghan Institute reveals the potential of hookworm therapy for patients in remission from ulcerative colitis, suggesting a path towards medication-free disease management—learn more about these groundbreaking findings.
Gastroenterology June 29th 2023
Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis
Five-hundred thirty-five (535) digitalized biopsies were graded against three standard indexes. A neural network was trained to distinguish remission from activity. The model predicted endoscopic-verified remission or activity with approximately 80% accuracy.
Gastroenterology March 29th 2023
MKSAP Quiz: Evaluation During Annual Follow-up Visit
A young woman with ulcerative colitis in remission on 5-ASA and azathioprine is seen for annual follow up. Immunizations are current and her depression and anxiety screens are negative. Review her current status and select the most important health maintenance screen.
Family Medicine/General Practice March 15th 2023
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients w. Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
As a TROP-2-directed antibody-drug conjugate with an SN-38 payload that has shown preliminary activity in metastatic urothelial carcinoma (mUC), sacituzumab govitecan (SG) – brand name Trodelvy –was evaluated and compared to current treatments to gauge whether SG objective response rates (ORRs) and median overall survival (OS) outperform the average of 10% ORR and 7 to 8 months OS.
Internal Medicine May 12th 2021
FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer
This new indication marks the second FDA approval for sacituzumab govitecan (Trodelvy, Immunomedics) and was based on the phase 2, single-arm TROPHY-U-01 main efficacy endpoints in objective response rate (ORR) and duration of response (DOR). With a relative 5-year survival rate of 5.5%, this is a significant advancement for patients with metastatic urothelial cancer (mUC), the most common type of bladder cancer.
Internal Medicine April 20th 2021